FurtekKJKubiakDWBarraMVarugheseCAAshbaughCDKooS.High incidence of neutropenia in patients with prolonged ceftaroline exposure. J Antimicrob Chemother. 2016;71:2010-2013. doi:10.1093/jac/dkw062.
3.
VaradaNLSakoulasGLeiLRChuaJ.Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin. Pharmacotherapy. 2015;35:608-612.
4.
JainRChanJDRogersLDellitTHLynchJBPottingerPS.High incidence of discontinuations due to adverse events in patients treated with ceftaroline. Pharmacotherapy. 2014;34:758-763.
5.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.